Kuo G, Choo Q L, Alter H J, Gitnick G L, Redeker A G, Purcell R H, Miyamura T, Dienstag J L, Alter M J, Stevens C E
Chiron Corporation, Emeryville, CA 94608.
Science. 1989 Apr 21;244(4902):362-4. doi: 10.1126/science.2496467.
A specific assay has been developed for a blood-borne non-A, non-B hepatitis (NANBH) virus in which a polypeptide synthesized in recombinant yeast clones of the hepatitis C virus (HCV) is used to capture circulating viral antibodies. HCV antibodies were detected in six of seven human sera that were shown previously to transmit NANBH to chimpanzees. Assays of ten blood transfusions in the United States that resulted in chronic NANBH revealed that there was at least one positive blood donor in nine of these cases and that all ten recipients seroconverted during their illnesses. About 80 percent of chronic, post-transfusion NANBH (PT-NANBH) patients from Italy and Japan had circulating HCV antibody; a much lower frequency (15 percent) was observed in acute, resolving infections. In addition, 58 percent of NANBH patients from the United States with no identifiable source of parenteral exposure to the virus were also positive for HCV antibody. These data indicate that HCV is a major cause of NANBH throughout the world.
已开发出一种针对血源性非甲非乙型肝炎（NANBH）病毒的特异性检测方法，其中利用丙型肝炎病毒（HCV）重组酵母克隆中合成的一种多肽来捕获循环中的病毒抗体。在先前显示可将NANBH传播给黑猩猩的七份人类血清中，有六份检测到了HCV抗体。对美国十例导致慢性NANBH的输血案例进行检测发现，其中九例至少有一名献血者呈阳性，并且所有十名受血者在患病期间都发生了血清转化。来自意大利和日本的约80%的慢性输血后NANBH（PT-NANBH）患者体内有循环HCV抗体；在急性、正在康复的感染中观察到的频率要低得多（15%）。此外，在美国没有可识别的经肠外途径接触该病毒来源的NANBH患者中，58%的人HCV抗体也呈阳性。这些数据表明，HCV是全世界NANBH的主要病因。
